<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00898118</url>
  </required_header>
  <id_info>
    <org_study_id>EWOG-MDS-SCT RC RIC-06</org_study_id>
    <secondary_id>CDR0000587523</secondary_id>
    <secondary_id>EU-20808</secondary_id>
    <nct_id>NCT00898118</nct_id>
  </id_info>
  <brief_title>Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant</brief_title>
  <official_title>Serial Analysis of Chimerism in Patients With Refractory Cytopenia (RC) Transplanted With Reduced Intensity Conditioning (RIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Working Group of MDS in Childhood</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help
      doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

      PURPOSE: This research study is looking at blood samples in young patients with cytopenia
      after undergoing a donor stem cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To study hematopoietic chimerism in whole blood and different cell populations (i.e.,
           CD14, CD15, CD 56, CD3, and CD19) as well as in dendritic cells and regulatory T cells
           after allogeneic hematopoietic stem cell transplantation with reduced intensity
           conditioning in patients with refractory cytopenia.

        -  To compare the results of chimerism obtained with standard short tandem nucleotide
           polymorphism PCR (sensitivity 1%) with those obtained with single nucleotide
           polymorphisms PCR (sensitivity 0.1- 0.01%).

      Secondary

        -  To evaluate the relationship between mixed chimerism and hematological engraftment,
           overall survival, and event-free survival.

        -  To study the impact of mixed chimerism in plasmacytoid dendritic and regulatory T cells
           on the incidence of acute and chronic graft-versus-host-disease.

      OUTLINE: This is a multicenter study.

      Peripheral blood is collected from patients and donors prior to hematopoietic stem cell
      transplantation (HSCT). Patients also undergo blood sample collection on days 30, 60, 100,
      and 180 after transplantation. Peripheral blood cells are enriched and separated into
      lineage-specific subpopulations (i.e., CD3, CD14, CD15, CD19, and CD56) which are then
      divided equally for either DNA isolation via PCR or for flow cytometry. DNA concentrations in
      pre-HSCT donor and patient samples and in post-HSCT subpopulation samples are determined
      using quantitative real-time PCR. Samples are also analyzed for quantification of chimerism
      and detection of genetic markers via short tandem repeats- and sequence nucleotide
      polymorphism-based chimerism analyses.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Number of patients with complete chimerism as measured by standard short tandem nucleotide polymorphism PCR in whole blood and the different cell populations</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with complete chimerism as measured by single nucleotide polymorphisms PCR in the different cell populations</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with mixed chimerism and full hematological recovery at day 100</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with mixed chimerism and acute or chronic graft-versus-host disease</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosed with refractory cytopenia

               -  Hypocellular bone marrow and normal karyotype

          -  Underwent stem cell transplantation (SCT) from an HLA identical (8/8) sibling, an HLA
             identical (10/10) relative, or an HLA identical or single allelic disparate unrelated
             donor

               -  Received a preparative regimen including either thiotepa or fludarabine phosphate

          -  Concurrently enrolled on EWOG-MDS-2006

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Bader, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Working Group of MDS in Childhood</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Anna Children's Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>43-1-401-700</phone>
      <email>trebo@ccri.univie.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ghent University</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>32-9240-3875</phone>
      <email>barbara.demoerloose@ugent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>42-022-443-6401</phone>
      <email>jan.stary@lfmotol.cuni.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital - Aarhus Sygehus</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>45-8949-6841</phone>
      <email>hasle@dadlnet.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>European Working Group of MDS in Childhood</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact</last_name>
      <phone>49-761-270-4617</phone>
      <email>Peter.Bader@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetskinderklinik - Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-761-270-4506</phone>
      <email>ewog-mds@uniklini-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS &quot;Casa Sollievo della Sofferenza&quot;</name>
      <address>
        <city>South Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact person</last_name>
      <phone>39-038-250-1251</phone>
      <email>m.zecca@smatteo.pv.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>31-104-636-691</phone>
      <email>m.vandenheuvel@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akademia Medyczna im. Piastow Slaskich</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>48-71-328-2040</phone>
      <email>wojcikd@pedhemat.am.wroc.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>41-44-266-7723</phone>
      <email>eva.bergstraesser@kispi.unizh.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>refractory cytopenia with multilineage dysplasia</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

